{
    "clinical_study": {
        "@rank": "95980", 
        "brief_summary": {
            "textblock": "To obtain preliminary information on the safety, tolerability, and antiretroviral activity\n      of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone.\n\n      PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated."
        }, 
        "brief_title": "The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT\n      alone for 12 weeks (AZT monotherapy arm eliminated per 1/19/96 amendment). All patients at a\n      given dose level of HBY 097 must be enrolled and adequate safety data obtained before\n      escalation in subsequent patients begins. Additional patients are entered at the optimal\n      dose of HBY 097. Patients are evaluated weekly for the first 4 weeks and then every 2 weeks\n      for the next 9 weeks.\n\n      PER AMENDMENT: Enrollment to the lowest dose cohort is completed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Treatment for opportunistic infection that develops on study.\n\n        Recommended:\n\n          -  PCP prophylaxis if CD4 count falls below 200 cells/mm3.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count 200 - 500 cells/mm3.\n\n          -  HIV-1 RNA PCR value of 10000 copies/ml or higher.\n\n          -  Asymptomatic or mildly symptomatic disease.\n\n          -  No past or current AIDS-defining event.\n\n          -  Consent of parent or guardian if less than legal age of consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Endocrine, hepatic, renal, or gastrointestinal disease.\n\n          -  Cardiovascular conduction disease.\n\n          -  Concomitant medical illness that may complicate study conduct or interpretation of\n             results.\n\n          -  Other factors that may interfere with patient compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents other than study drugs.\n\n          -  Oral contraceptives.\n\n          -  Cytotoxic chemotherapy.\n\n          -  Immunomodulators.\n\n          -  Antiproliferative agents.\n\n          -  Corticosteroids.\n\n          -  Anabolic steroids.\n\n          -  Estrogens.\n\n          -  Quinoxaline derivatives.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of hypersensitivity to quinoxaline derivatives or intolerance to AZT.\n\n          -  History of cardiovascular conduction disease.\n\n          -  Prior participation in this study or any study using HBY 097.\n\n          -  Recent use of a drug that interferes with drug metabolism, absorption, distribution,\n             or excretion.\n\n          -  History of thyroid disease.\n\n        Prior Medication:\n\n        Excluded at any time:\n\n        Prior non-nucleoside reverse transcriptase inhibitors.\n\n        Excluded within 30 days prior to study entry:\n\n          -  Any antiretroviral therapy.\n\n          -  Oral contraceptives.\n\n          -  Immunomodulating agents such as systemic corticosteroids, interleukins, or\n             interferons.\n\n          -  Cytotoxic chemotherapeutic agents.\n\n          -  Other investigational drugs.\n\n        Excluded within 6 months prior to study entry:\n\n        Immunotherapeutic vaccine.\n\n        Prior Treatment:\n\n        Excluded within 30 days prior to study entry:\n\n          -  Radiation therapy.\n\n          -  An experimental device. Current ethanol or illicit drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "144", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002357", 
            "org_study_id": "252A", 
            "secondary_id": "HBY097/2001"
        }, 
        "intervention": [
            {
                "intervention_name": "HBY 097", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Los Angeles County - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "943055107"
                    }, 
                    "name": "Stanford Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Med College of Georgia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77006"
                    }, 
                    "name": "Houston Clinical Research Network"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002357"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoechst Marion Roussel", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1997"
    }, 
    "geocoordinates": {
        "Georgetown Univ Med Ctr": "38.895 -77.036", 
        "Houston Clinical Research Network": "29.76 -95.369", 
        "Los Angeles County - USC Med Ctr": "34.052 -118.244", 
        "Med College of Georgia": "33.474 -82.01", 
        "New York Univ Med Ctr": "40.714 -74.006", 
        "Stanford Univ School of Medicine": "37.429 -122.169"
    }
}